Full-Time

Manager – Consumer Marketing

Invivyd

Invivyd

51-200 employees

Develops monoclonal antibodies for viral protection

Compensation Overview

$140k - $160k/yr

+ Short-Term Incentive + Equity

United States

Hybrid

Local candidates preferred; in-office presence up to 30%.

Bachelor's, MBA

Category
Growth & Marketing (1)
Required Skills
Social Media
Marketing
Data Analysis

Get referred to Invivyd

See people who can refer or advise you

Requirements
  • Bachelor’s degree in Marketing, Communications, Business, or related field required; MBA or advanced degree preferred.
  • Minimum 5 years of marketing experience
  • Strong understanding of pharmaceutical advertising and promotion regulations
  • Proven ability to manage multiple projects and external agencies in a fast-paced, matrixed environment
  • Strong ability to derive actionable insights from multiple and complex sources
  • Strong understanding of and hands-on experience in managing workflows through legal and regulatory promotional review process
Responsibilities
  • Support Director of Consumer Marketing and associated agency partners, ensuring shared accountability to the brand strategy, rigor in marketing excellence, and exceptional execution of key social media plan tactics and deliverables.
  • Guide and oversee tactical implementation and ongoing optimization of the EUA compliant consumer marketing plans.
  • Support development and execution of integrated launch campaigns for new product launch. Collaborate with cross-functional partners to ensure readiness and flawless execution.
  • Build and scale social media influencer campaigns and ensure alignment with brand voice and adherence to regulatory requirements.
  • Support the development of patient-facing materials and campaigns including educational resources, digital and social media content, testimonials, videos, brochures, and website content ensuring a consistent and compliant brand message across all touchpoints.
  • Collaborate with patient services and advocacy to support marketing material needs and develop targeted programming.
  • Ensure timely understanding, measurement and evaluation of brand performance and work collaboratively withing the marketing team to modify tactical plans as needed.
  • Oversee agency partners to develop and execute creative campaigns across digital, print, and social media platforms.
  • Manage project timelines, budgets, and deliverables to ensure high-quality execution and alignment with strategic priorities
Desired Qualifications
  • Consumer marketing experience in pharma, biotech, consumer health or OTC categories
  • Commitment to Invivyd’s Core Values: united, determined, dynamic, proactive, spirited
  • Strong preference for local candidates as in-office presence of up to 30% is required

Invivyd develops antibody-based therapies to protect immunocompromised people from viral threats. It discovers and optimizes monoclonal antibodies using viral surveillance, predictive modeling, and antibody engineering, aiming to prevent infections such as COVID-19 in high-risk groups. Its lead candidate VYD222 targets prevention of symptomatic COVID-19 in transplant recipients and people with blood cancers. The company plans to commercialize these antibodies through development, approvals, and partnerships, while pursuing government funding to support research for vulnerable populations.

Company Size

51-200

Company Stage

IPO

Headquarters

Waltham, Massachusetts

Founded

2020

Get referred to Invivyd

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 PEMGARDA revenue reached $14.3 million, up 21% year over year.
  • Invivyd completed enrollment for DECLARATION and LIBERTY, with data expected late Q3 2026.
  • April 2026 sample-size re-estimation and June upsizing boosted statistical power and credibility.

What critics are saying

  • Invivyd disclosed substantial doubt about going concern in May 2026 without new financing.
  • Nasdaq warned on July 23, 2026 after IVVD stayed below $1.00 for 30 days.
  • If DECLARATION disappoints in Q3 2026, Invivyd loses its only near-term value driver.

What makes Invivyd unique

  • Invivyd owns fast-moving antibody engineering for immune-compromised viral prophylaxis, led by VYD2311.
  • DECLARATION’s upsized 2,400-patient design targets symptomatic COVID with BLA-enabling readout in Q3 2026.
  • Michael Mina joined as CMO, adding credibility in vaccine alternative and public-health positioning.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Professional Development Budget

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

0%

2 year growth

-2%
Yahoo Finance
May 18th, 2026
Invivyd reports $13.7M Q1 revenue, 22% growth, advances COVID-19 monoclonal antibody trial

Invivyd Inc. reported first-quarter earnings on 14 May, with PEMGARDA net product revenue reaching $13.7 million, up 22% year-on-year. The biopharmaceutical company ended the quarter with $184.2 million in cash, supplemented by approximately $20 million from an at-the-market offering in April. The company posted a net loss of $41.4 million, driven by increased operating expenses related to its DECLARATION Phase 3 clinical trial for VYD2311, a COVID-19 monoclonal antibody candidate. The trial achieved initial full enrollment in March, with top-line data now expected in the third quarter. Invivyd is preparing additional Phase 3 trials and advancing its pipeline beyond COVID-19, including VMS063 for measles and VBY329 for paediatric respiratory syncytial virus prophylaxis.

Yahoo Finance
May 14th, 2026
Invivyd reports 22% YoY PEMGARDA revenue growth amid clinical trial investments

Invivyd Inc reported strong revenue growth in its Q1 2026 earnings call, with monoclonal antibody revenues continuing to grow and PEMGARDA revenue increasing 22% year-over-year compared to Q1 2025. The company accelerated recruitment for its pivotal DECLARATION trial, exceeding internal expectations, though recruitment slowed during a lull in COVID-19 cases. The company confirmed virus neutralisation against the Omicron BA.3.2 variant and is expanding its early discovery pipeline to include antibodies for measles, mumps, rubella and Lyme disease. Invivyd reported significant clinical spending on the DECLARATION trial but expects R&D spending to normalise as the VYD2311 trial concludes. The company strengthened its cash position through additional funding raised in April and received positive feedback from policymakers on increased government affairs activity.

Yahoo Finance
Mar 5th, 2026
Invivyd eyes mid-2026 data for COVID antibody VYD2311 as PEMGARDA revenue jumps 31%

Invivyd reported Q4 2025 earnings, highlighting strategic progress in monoclonal antibody prophylaxis as an alternative to COVID-19 vaccine boosting. The company's Declaration study for VYD2311 reached target enrolment of approximately 1,770 subjects, with mid-year 2026 remaining the target for pivotal data. PEMGARDA revenue grew 31% sequentially, supporting infrastructure development ahead of a potential VYD2311 launch. Management expects to decide on expanding the trial by roughly 30% in April to ensure statistical power if community attack rates fluctuate. The company reported cash of $226.7 million, providing runway through the mid-2026 data readout. Invivyd is expanding into long COVID and post-vaccine syndrome, whilst developing RSV and measles programmes with a paediatric-first approach. Management cited COVID-19 community attack rates as the primary external risk factor.

Yahoo Finance
Mar 5th, 2026
Invivyd reports $17.2M Q4 revenue for PEMGARDA, raises $200M to fund VYD2311 COVID trial

Invivyd reported fourth quarter 2025 net product revenue of $17.2 million for PEMGARDA (pemivibart), representing 25% year-over-year growth and 31% quarter-over-quarter growth. Full-year revenue more than doubled whilst operating expenses were reduced by nearly half. The company ended 2025 with $226.7 million in cash after raising over $200 million in financing transactions during the second half of the year. Invivyd has initiated the DECLARATION Phase 3 pivotal trial of VYD2311, a vaccine-alternative antibody to prevent COVID, with top-line data expected mid-2026. The FDA granted Fast Track designation for VYD2311 in December 2025. The trial has achieved full enrolment and an independent data monitoring committee has recommended allowing pregnant and breastfeeding women to participate. A potential trial re-sizing decision could occur in April.

Yahoo Finance
Mar 5th, 2026
Invivyd appoints Harvard epidemiologist Michael Mina as chief medical officer

Invivyd has appointed Michael Mina, M.D., Ph.D., as Chief Medical Officer. Dr Mina is a former assistant professor of epidemiology, immunology and infectious disease at Harvard T.H. Chan School of Public Health and pathology at Harvard Medical School and Brigham and Women's Hospital. Dr Mina gained prominence during the COVID pandemic, advising governments on testing policies and leading the US government's Home Test-to-Treat Programme. His research includes discovering measles-induced "immune amnesia" and investigating antibody responses to vaccines and pathogens. He has published over 100 scientific papers with more than 10,000 citations. The appointment comes as Invivyd works to expand its pipeline of monoclonal antibodies for infectious disease prevention, including COVID, RSV and measles.